Introduced in 1981, Zantac became the world’s largest-selling prescription drug by 1987. To date, hundreds of thousands of people have been prescribed the medication for heartburn and acid reflux.
However, recent scientific studies have shown that ranitidine, the active ingredient in Zantac, metabolizes into a substance known as N-Nitrosodimethylamine (NDMA) inside the body. NDMA, a component found in rocket fuel, is considered a probable human carcinogen by the Food and Drug Administration (FDA). Cancers linked to NDMA include bladder, breast, colon, esophageal, kidney, liver, ovarian, prostate, stomach, and melanoma.
Evidence linking NDMA to cancer was so convincing that the FDA ordered a recall of the drug in April of 2020. Plaintiffs in lawsuits against the makers of Zantac say that the company failed to adequately warn consumers of the cancer risks associated with the medication.
If your firm would like to help plaintiffs with NDMA-related cancer, Reliance Litigation, LLC can help you. We provide all your marketing needs, including advanced screening of potential clients and contract-signing services.
Call (888) 780-8911 or fill out the form below to find out more about our quality services.